Investigational antimicrobial agents of 2013

Clinical Microbiology Reviews

Volumn 26, Issue 4, 2013, Pages 792-821

  Pucci, Michael J ^a   Bush, Karen ^b  

^a Achillion Pharmaceuticals   (United States)

^b INDIANA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACT 179811; AFN 1252; ANTIINFECTIVE AGENT; AVAROFLOXACIN; AVIBACTAM; AZTREONAM; BAL 30072; BC 3781; BC 7013; BIAPENEM; BRILACIDIN; CADAZOLID; CEFTAROLINE; DELAFLOXACIN; DELAMANID; DS 8587; ERAVACYCLINE; FUSIDATE SODIUM; FUSIDIC ACID; GSK 2251052; KPI 10; LCB 01 0371; LFF 571; MRX 1; MUT 056339; MUT 056399; NEMONOXACIN; NVB 302; PLACEBO; POL 7080; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RPX 2003; RPX 7009; TG 875649; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ABDOMINAL INFECTION; ANTIBIOTIC RESISTANCE; BACTEREMIA; BACTERIAL INFECTION; CLOSTRIDIUM DIFFICILE INFECTION; COMMUNITY ACQUIRED PNEUMONIA; DIABETIC FOOT; DRUG ABSORPTION; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENCY; DRUG SAFETY; DRUG STABILITY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; GASTROINTESTINAL SYMPTOM; GENE MUTATION; HAEMOPHILUS INFECTION; HOSPITAL INFECTION; HUMAN; INFECTIOUS ARTHRITIS; KLEBSIELLA PNEUMONIAE INFECTION; LOADING DRUG DOSE; LUNG INFECTION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; MULTICENTER STUDY (TOPIC); NONHUMAN; PARESTHESIA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; PSEUDOMONAS INFECTION; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEPTICEMIA; SINGLE DRUG DOSE; SKIN DISEASE; SKIN INFECTION; SKIN TINGLING; SOFT TISSUE INFECTION; STAPHYLOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIA; TUBERCULOSIS; UNSPECIFIED SIDE EFFECT; URINARY TRACT INFECTION;

ANTI-BACTERIAL AGENTS; ANTITUBERCULAR AGENTS; BACTERIAL PROTEINS; BETA-LACTAMASES; BETA-LACTAMS; CLINICAL TRIALS AS TOPIC; CLOSTRIDIUM INFECTIONS; DRUG COMBINATIONS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUGS, INVESTIGATIONAL; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; HEALTH SURVEYS; HUMANS; MOLECULAR MIMICRY; PROTEIN SYNTHESIS INHIBITORS; TOPOISOMERASE INHIBITORS; TUBERCULOSIS;

EID: 84884961808     PISSN: 08938512     EISSN: 10986618     Source Type: Journal    
DOI: 10.1128/CMR.00033-13     Document Type: Review

References (260)

1. Gould IM. 2010. Coping with antibiotic resistance: the impending crisis. Int. J. Antimicrob. Agents 36:(Suppl 3):S1-S2.
2. Piddock LJ. 2012. The crisis of no new antibiotics-what is the way forward? Lancet Infect. Dis. 12:249-253.
3. Tremolieres F, Cohen R, Gauzit R, Vittecoq D, Stahl JP. 2010. Save antibiotics. What can be done to prevent a forecasted disaster! Suggestions to promote the development of new antibiotics. Med. Malad. Infect. 40:129-134.
4. Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB, Scheld M, Spellberg B, Bartlett J. 2009. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin. Infect. Dis. 48:1-12.
5. Mazel D, Davies J. 1999. Antibiotic resistance in microbes. Cell. Mol. Life Sci. 56:742-754.
6. Chan M. 14 March 2012, posting date. Antimicrobial resistance in the European Union and the world. http://www.who.int/dg/speeches/2012 /amr_20120314/en/.
7. Shlaes DM. 4 September 2012. New antibiotics? Go public! http://antibiotics-theperfectstorm.blogspot.com/2012/09/new-antibiotics-go-public.html.
8. Butler MS, Cooper MA. 2011. Antibiotics in the clinical pipeline in 2011. J. Antibiot. 64:413-425.
9. Bush K, Pucci MJ. 2011. New antimicrobial agents on the horizon. Biochem. Pharmacol. 82:1528-1539.
10. Sutcliffe JA. 2011. Antibiotics in development targeting protein synthesis. Ann. N. Y. Acad. Sci. 1:122-152.
11. Boucher HW, Talbot GH, Benjamin DK, Bradley J, Guidos RJ, Jones RN, Murray BE, Bonomo RA, Gilbert D. 2013. 10 × ′20 Progress-development of new drugs active against Gram-negative bacilli: an update from the Infectious Diseases Society of America. Clin. Infect. Dis. 56:1685-1694.
12. Bush K. 2012. Improving known classes of antibiotics: an optimistic approach for the future. Curr. Opin. Pharmacol. 12:527-534.
13. Wang X, Zhao X, Malik M, Drlica K. 2010. Contribution of reactive oxygen species to pathways of quinolone-mediated bacterial cell death. J. Antimicrob. Chemother. 65:520-524.
14. Collin F, Karkare S, Maxwell A. 2011. Exploiting bacterial DNA gyrase as a drug target: current state and perspectives. Appl. Microbiol. Biotechnol. 92:479-497.
15. Wiles JA, Bradbury BJ, Pucci MJ. 2010. New quinolone antibiotics: a survey of the literature from 2005 to 2010. Exp. Opin. Ther. Pat. 20:1295-1319.
16. Mitscher LA. 2005. Bacterial topoisomerase inhibitors: quinolone and pyridone antibacterial agents. Chem. Rev. 105:559-592.
17. Lauderdale TL, Shiau YR, Lai JF, Chen HC, King CH. 2010. Comparative in vitro activities of nemonoxacin (TG-873870), a novel nonfluorinated quinolone, and other quinolones against clinical isolates. Antimicrob. Agents Chemother. 54:1338-1342.
18. Adam HJ, Laing NM, King CR, Lulashnyk B, Hoban DJ, Zhanel GG. 2009. In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. Antimicrob. Agents Chemother. 53: 4915-4920.
19. van Rensburg DJ, Perng RP, Mitha IH, Bester AJ, Kasumba J, Wu RG, Ho ML, Chang LW, Chung DT, Chang YT, King CH, Hsu MC. 2010. Efficacy and safety of nemonoxacin versus levofloxacin for communityacquired pneumonia. Antimicrob. Agents Chemother. 54:4098-4106.
20. Kuramoto Y, Ohshita Y, Yoshida J, Yazaki A, Shiro M, Koike T. 2003. A novel antibacterial 8-chloroquinolone with a distorted orientation of the N1-(5-amino-2,4-difluorophenyl) group. J. Med. Chem. 46:1905-1917.
21. Remy JM, Tow-Keogh CA, McConnell TS, Dalton DeVito JM JA. 2012. Activity of delafloxacin against methicillin-resistant Staphylococcus aureus: resistance selection and characterization. J. Antimicrob. Chemother. 67:2814-2820.
22. Almer LS, Hoffrage JB, Keller EJ, Flamm RK, Shortridge VD. 2004. In vitro and bactericidal activities of ABT-492, a novel fluoroquinolone, against Gram-positive and Gram-negative organisms. Antimicrob. Agents Chemother. 48:2771-2777.
23. Nilius AM, Shen LL, Hensey-Rudloff D, Almer LS, Beyer JM, Balli DJ, Cai Y, Flamm RK. 2003. In vitro antibacterial potency and spectrum of ABT-492, a new fluoroquinolone. Antimicrob. Agents Chemother. 47: 3260-3269.
24. Lawrence L, Benedict M, Hart J, Hawkins A, Li D, Medlock M, Hopkins S, Burak E. 2011. Pharmacokinetics (PK) and safety of single doses of delafloxacin administered intravenously in healthy human subjects. Abstr. 51st Intersci. Conf. Antimicrob. Agents Chemother., abstr A2-045.
25. Stubbings W, Leow P, Yong GC, Goh F, Körber-Irrgang B, Kresken M, Endermann R, Labischinski H. 2011. In vitro spectrum of activity of finafloxacin, a novel, pH-activated fluoroquinolone, under standard and acidic conditions. Antimicrob. Agents Chemother. 55:4394-4397.
26. Emrich NC, Heisig A, Stubbings W, Labischinski H, Heisig P. 2010. Antibacterial activity of finafloxacin under different pH conditions against isogenic strains of Escherichia coli expressing combinations. J. Antimicrob. Chemother. 65:2530-2533.
27. Higgins PG, Stubbings W, Wisplinghoff H, Seifert H. 2010. Activity of the investigational fluoroquinolone finafloxacin against ciprofloxacinsensitive and-resistant Acinetobacter baumannii. Antimicrob. Agents Chemother. 54:1613-1615.
28. Park HS, Kim HJ, Seol MJ, Choi DR, Choi EC, Kwak JH. 2006. In vitro and in vivo antibacterial activities of DW-224a, a new fluoronaphthyridone. Antimicrob. Agents Chemother. 50:2261-2264.
29. Kim EJ, Shin WH, Kim KS, Han SS. 2004. Safety pharmacology of DW-224a, a novel fluoroquinolone antibiotic agent. Drug Chem. Toxicol. 27:295-307.
30. Farrell DJ, Liverman LC, Biedenbach DJ, Jones RN. 2011. JNJ-Q2, a new fluoroquinolone with potent in vitro activity against Staphylococcus aureus, including methicillin-and fluoroquinolone-resistant strains. Antimicrob. Agents Chemother. 55:3631-3634.
31. Morrow BJ, He W, Amsler KM, Foleno BD, Macielag MJ, Lynch AS, Bush K. 2010. In vitro antibacterial activities of JNJ-Q2, a new broadspectrum fluoroquinolone. Antimicrob. Agents Chemother. 54:1955-1964.
32. Covington P, Davenport JM, Andrae D, O'Riordan W, Liverman l, McIntyre G, Almenoff J. 2011. Randomized, double-blind, phase 2, multicenter study evaluating the safety/tolerability and efficacy of JNJQ2, a novel fluoroquinolone, compared with linezolid for treatment of acute bacterial skin and skin structure infection. Antimicrob. Agents Chemother. 55:5790-5797.
33. Chiba M, Fujikawa K, Okumura R, Yuichi K, Hoshino K. 2012. DS-8587, a new generation of broad spectrum quinolone: antibacterial spectrum and its in vitro activity against clinical isolates in Japan. Abstr. 52nd Intersci. Conf. Antimicrob. Agents Chemother. abstr F-2037.
34. Higuchi S, Onodera Y, Chiba M, Hoshino K, Gotoh N. 2013. Potent in vitro antibacterial activity of DS-8587, a novel broad-spectrum quinolone, against Acinetobacter baumannii. Antimicrob. Agents Chemother. 57:1978-1981.
35. Kurosaka Y, Ubyama S, Ishii K, Hoshino K. 2012. DS-8587, a new generation of broad spectrum quinolone: pharmacodynamic and therapeutic efficacy in animal infection models. Abstr. 52nd Intersci. Conf. Antimicrob. Agents Chemother. abstr F-2035.
36. Miida H, Tsuchiya Y, Itoh S, Noritake K, Ishizawa T, Takasaki W. 2012. DS-8587, a new generation of broad spectrum quinolone: safety profile in preclinical studies. Abstr. 52nd Intersci. Conf. Antimicrob. Agents Chemother. abstr F-2042.
37. Flamm RK, Biedenbach DJ, Sader HS, Konrardy ML, Jones RN. 2012. KPI-10, a novel fluoroquinolone (FQ) tested against Neisseria gonorrhoeae including ciprofloxacin non-susceptible (CIP-NS) and penicillin non-susceptible (PEN-NS) strains. Abstr. 52nd Intersci. Conf. Antimicrob. Agents Chemother., abstr F-2052.
38. Deane J, Simenauer A, Ge Y, Eckburg PB, Sahm D. 2012. In vitro activity of KPI-10 against clinically important Gram-negative bacteria. Abstr. 52nd Intersci. Conf. Antimicrob. Agents Chemother., abstr F-2046.
39. Deane J, Simenauer A, Ge Y, Eckburg PB, Sahm D. 2012. In vitro activity of KPI-10 against clinically important Gram-negative bacteria. Abstr. 52nd Intersci. Conf. Antimicrob. Agents Chemother., abstr F-2047.
40. Eckburg PB, Ge Y, Jiang V, Kilfoil T, Talbot GH. 2012. Safety & pharmacokinetics of KPI-10, a novel fluoroquinolone, in healthy adults receiving single-dose oral administrations. Abstr. 52nd Intersci. Conf. Antimicrob. Agents Chemother. abstr F-2047.
41. Morrissey I, Janes R, Dallow J, Leakey A, Gugliett A, Gargallo-Viola D. 2012. Ozenoxacin. Activity against Gram-positive bacteria (GPB) causing skin and soft tissue infections (SSTI) collected in 2009-10. Abstr. 52nd Intersci. Conf. Antimicrob. Agents Chemother., abstr B-1302.
42. Li GQ, Yuan M, Yang XY, Li CR, Hu XX, Zhang WX, Lou RH, Guo HY, You XW, Cen S, Jiang JD, You XF. 2012. In vitro antibacterial activity of chinfloxacin, a new fluoroquinolone antibiotic. Chemotherapy 58:175-184.
43. Li GQ, Bai XG, Li CR, Yang XY, Hu XX, Yuan M, Zhang WX, Lou RH, Guo HY, Jiang JD, You XF. 2012. In vivo antibacterial activity of chinfloxacin, a new fluoroquinolone antibiotic. J. Antimicrob. Chemother. 67:955-961.
44. Chu DT, Fernandes PB, Claiborne AK, Shen L, Pernet AG. 1988. Structure-activity relationships in quinolone antibacterials: design, synthesis and biological activities of novel isothiazoloquinolones. Drugs Exp. Clin. Res. 14:379-383.
45. Pucci MJ, Cheng J, Podos SD, Thoma CL, Thanassi JA, Buechter DD, Mushtaq G, Vigliotti GA, Jr, Bradbury BJ, Deshpande M. 2007. In vitro and in vivo antibacterial activities of heteroaryl isothiazolones against resistant Gram-positive pathogens. Antimicrob. Agents Chemother. 51: 1259-1267.
46. Pucci MJ, Podos SD, Thanassi JA, Leggio MJ, Bradbury BJ, Deshpande M. 2011. In vitro and in vivo profiles of ACH-702, an isothiazoloquinolone, against bacterial pathogens. Antimicrob. Agents Chemother. 55:2860-2871.
47. Waksman SA, Schatz A, Reynolds DM. 1946. Production of antibiotic substances by actinomycetes. Ann. New York Acad. Sci. 48:73-85.
48. Moazed D, Noller HF. 1987. Interaction of antibiotics with functional sites in 16S ribosomal RNA. Nature 327:389-394.
49. Nicolau DP, Freeman CD, Belliveau PP, Nightingale CH, Ross JW, Quintiliani R. 1995. Experience with a once-daily aminoglycoside program administered to 2,184 adult patients. Antimicrob. Agents Chemother. 39:650-655.
50. Aggen JB, Armstrong ES, Goldblum AA, Dozzo P, Linsell MS, Gliedt MJ, Hildebrandt DJ, Feeney LA, Kubo A, Matias RD, Lopez S, Gomez M, Wlasichuk KB, Diokno R, Miller GH, Moser HF. 2010. Synthesis and spectrum of the neoglycoside ACHN-490. Antimicrob. Agents Chemother. 54:4636-4642.
51. Armstrong ES, Miller GH. 2010. Combating evolution with intelligent design: the neoglycoside ACHN-490. Curr. Opin. Microbiol. 13:565-573.
52. Endimiani A, Hujer KM, Hujer AM, Armstrong ES, Choudhary Y, Aggen JB, Bonomo RA. 2009. ACHN-490, a neoglycoside with potent in vitro activity against multidrug-resistant Klebsiella pneumoniae isolates. Antimicrob. Agents Chemother. 53:4504-4507.
53. Livermore DM, Mushtaq S, Warner SM, Zhang JC, Maharjan S, Doumith M, Woodford N. 2011. Activity of aminoglycosides, including ACHN-490, against carbapenem-resistant Enterobacteriaceae isolates. J. Antimicrob. Chemother. 66:48-53.
54. Tenover FC, Tickler I, Armstrong ES, Kubo A, Lopez S, Persing DH, Miller GH. 2011. Activity of ACHN-490 against meticillin-resistant Staphylococcus aureus (MRSA) isolates from patients in US hospitals. Int. J. Antimicrob. Agents 38:352-354.
55. Landman D, Kelly P, Backer M, Babu F, Shah N, Bratu S, Quale J. 2011. Antimicrobial activity of a novel aminoglycoside, ACHN-490, against Acinetobacter baumannii and Pseudomonas aeruginosa from New York City. J. Antimicrob. Chemother. 66:332-334.
56. Reyes N, Aggen JB, Kostrub CF. 2011. In vivo efficacy of the novel aminoglycoside ACHN-490 in murine infection models. Antimicrob. Agents Chemother. 55:1728-1733.
57. Heine HS, Chuvala L, Riggins R, Hurteau G, Cass R, Cirz R. 2012. Efficacy of plazomicin against Yersinia pestis in a murine-aerosol challenge late-treatment model. Abstr. 52nd Intersci. Conf. Antimicrob. Agents Chemother., abstr B-1302.
58. Mega W, Cirz R, Cass R, Reyes N, Valderas M, Sherwood R. 2012. Efficacy of intravenous plazomicin in the African green monkey (AGM) inhalational plague model. Abstr. 52nd Intersci. Conf. Antimicrob. Agents Chemother., abstr B-1308a.
59. Louie A, Fikes S, Liu W, VanScoy B, Cirz R, Drusano G. 2012. Pharmacodynamics of plazomicin in a neutropenic murine pneumonia model against Klebsiella pneumoniae (Kpn). Abstr. 52nd Intersci. Conf. Antimicrob. Agents Chemother., abstr A-041.
60. Cass RT, Brooks CD, Havrilla NA, Tack KJ, Borin MT, Young D, Bruss JB. 2011. Pharmacokinetics and safety of single and multiple doses of ACHN-490 injection administered intravenously in healthy subjects. Antimicrob. Agents Chemother. 55:5874-5880.
61. Riddle V, Cebrik D, Armstrong E, Cass R, Clobes T, Hillan K, Crofton. 2012. Plazomicin safety and efficacy in patients with complicated urinary tract infection (cUTI) or acute pyelonephritis (AP). Abstr. 52nd Intersci. Conf. Antimicrob. Agents Chemother., abstr L-2118a.
62. Nelson ML, Levy SB. 2011. The history of the tetracyclines. Ann. New York Acad. Sci. 1241:17-32.
63. Sum PE, Petersen P. 1999. Synthesis and structure-activity relationship of novel glycylcycline derivatives leading to the discovery of GAR-936. Bioorg. Med. Chem. Lett. 9:1459-1462.
64. Petersen PJ, Jacobus NV, Weiss WJ, Sum PE, Testa RT. 1999. In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-tbutylglycylamido derivative of minocycline (GAR-936). Antimicrob. Agents Chemother. 43:738-744.
65. Macone A, Donatelli J, Dumont T, Levy SB, Tanaka SK. 2003. In vitro activity of PTK0796 (BAY 73-6944) against Gram-positive and Gramnegative organisms. Abstr. 43rd Intersci. Conf. Antimicrob. Agents Chemother., abstr 2439.
66. Traczewski MM, Brown SD. 2003. PTK 0796 (BAY 73-6944): in vitro potency and spectrum of activity compared to ten other antimicrobial compounds, Abstr. 43rd Intersci. Conf. Antimicrob. Agents Chemother., abstr 2458.
67. Ruzin A, Petrone P, Whitehead L, Bradford PA. 2011. Omadacycline (PTK796) mechanism of action studies by using in vitro protein synthesis inhibition assay and molecular modeling. Abstr. 51st Intersci. Conf. Antimicrob. Agents Chemother., abstr C1-609.
68. Weir S, Macone A, Donatelli J, Trieber C, Taylor DE, Tanaka SK, Levy SB. 2003. The activity of PTK0796 against tetracycline resistance. Abstr. 43rd Intersci. Conf. Antimicrob. Agents Chemother., abstr F-752.
69. Ruzin A, Dzink-Fox J, Jones AK, Dean CR, Bradford PA. 2010. Studies on the mechanism of resistance to PTK796 in Pseudomonas aeruginosa and Klebsiella pneumoniae. Abstr. 50th Intersci. Conf. Antimicrob. Agents Chemother., abstr C1-1079.
70. Sun H, Ting L, Flarakos J, Dole K, Praestgaard J, Kovacs SJ, Stein DS, Sunkara G, Tanaka SK. 2012. Pharmacokinetics of [14c]-labeled omadacycline (PTK 0796) in healthy male subjects. Abstr. 52nd Intersci. Conf. Antimicrob. Agents Chemother., abstr A-1281.
71. Macone AB, Arbeit RD, Hait HI, Draper MP, Tanaka SK. 2010. Identification and susceptibility of pathogens isolated from patients with complicated skin and skin structure infections (cSSSI): results of a PTK 0796 (PTK) phase 2 clinical trial. Abstr. 50th Intersci. Conf. Antimicrob. Agents Chemother., abstr L1-1760.
72. O'Brien W, Sutcliffe J, Grossman T. 2012. Eravacycline (TP-434) is active in vitro against biofilms formed by uropathogenic Escherichia coli. Abstr. 52nd Intersci. Conf. Antimicrob. Agents Chemother., abstr E-777.
73. Horn P, Cesnauskas G, Ramesh M, Walpole S, Sutcliffe J, Solomkin J. 2012. Efficacy and safety of TP-434 versus ertapenem in complicated intra-abdominal infection (cIAI). Abstr. 52nd Intersci. Conf. Antimicrob. Agents Chemother., abstr L1-1647a.
74. Grossman TH, Fyfe C, Brien WO, Hackel M, Sutcliffe JA. 2012. TP-271 is a potent, broad-spectrum fluorocycline with activity against community-acquired bacterial respiratory and biothreat pathogens. Abstr. 52nd Intersci. Conf. Antimicrob. Agents Chemother., abstr F-1525.
75. Dunkle JA, Xiong L, Mankin AS, Cate JH. 2010. Structures of the Escherichia coli ribosome with antibiotics bound near the peptidyl transferase center explain spectra of drug action. Proc. Nat. Acad. Sci. U. S. A. 107:17152-17157.
76. Washington JA 2nd, Wilson WR. 1985. Erythromycin: a microbial and clinical perspective after 30 years of clinical use (1). Mayo Clin. Proc. 60:189-203.
77. Zhong P, Shortridge V. 2001. The emerging new generation of antibiotic: ketolides. Curr. Drug Targets Infect. Disord. 1:125-131.
78. Bemer-Melchior P, Juvin ME, Tassin S, Bryskier A, Schito GC, Drugeon HB. 2000. In vitro activity of the new ketolide telithromycin compared with those of macrolides against Streptococcus pyogenes: influences of resistance mechanisms and methodological factors. Antimicrob. Agents Chemother. 44:2999-3002.
79. Echols RM. 2011. Understanding the regulatory hurdles for antibacterial drug development in the post-Ketek world. Ann. N. Y. Acad. Sci. 1:153-161.
80. Capobianco JO, Cao Z, Shortridge VD, Ma Z, Flamm RK, Zhong P. 2000. Studies of the novel ketolide ABT-773: transport, binding to ribosomes, and inhibition of protein synthesis in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 44:1562-1567.
81. Rafie S, MacDougall C, James CL. 2010. Cethromycin: a promising new ketolide antibiotic for respiratory infections. Pharmacotherapy 30:290-303.
82. Mansour H, Chahine EB, Karaoui LR, El-Lababidi RM. 2013. Cethromycin: a new ketolide antibiotic. Ann. Pharmacother. 47:368-379.
83. Rodgers W, Frazier AD, Champney WS. 2013. Solithromycin inhibition of protein synthesis and ribosome biogenesis in Staphylococcus aureus, Streptococcus pneumoniae, and Haemophilus influenzae. Antimicrob. Agents Chemother. 57:1632-1637.
84. Farrell DJ, Castanheira M, Sader HS, Jones RN. 2010. The in vitro evaluation of solithromycin (CEM-101) against pathogens isolated in the United States and Europe (2009). J. Infect. 61:476-483.
85. Putnam SD, Sader HS, Farrell DJ, Biedenbach DJ, Castanheira M. 2011. Antimicrobial characterisation of solithromycin (CEM-101), a novel fluoroketolide: activity against staphylococci and enterococci. Int. J. Antimicrob. Agents 37:39-45.
86. Bertrand D, Bertrand S, Neveu E, Fernandes P. 2010. Molecular characterization of off-target activities of telithromycin: a potential role for nicotinic acetylcholine receptors. Antimicrob. Agents Chemother. 54:5399-5402.
87. Still JG, Schranz J, Degenhardt TP, Scott D, Fernandes P, Gutierrez MJ, Clark K. 2011. Pharmacokinetics of solithromycin (CEM-101) after single or multiple oral doses and effects of food on single-dose bioavailability in healthy adult subjects. Antimicrob. Agents Chemother. 55: 1997-2003.
88. Barbachyn MR. 2012. Oxazolidinone antibacterial agents, p 271-299. In Dougherty TJ, Pucci MJ (ed), Antibacterial drug discovery and development. Springer Publishers, New York, NY.
89. Fugitt RB, Luckenbaugh RW. December 1978. 5-Halomethyl-3-phenyl-2-oxazolidinones. US patent 4,128,654.
90. Shaw KJ, Barbachyn MR. 2011. The oxazolidinones: past, present, and future. Ann. N. Y. Acad. Sci. 1241:48-70.
91. Slee AM, Wuonola MA, McRipley RJ, Zajac I, Zawada MJ, Bartholomew PT, Gregory WA, Forbes M. 1987. Oxazolidinones, a new class of synthetic antibacterial agents: in vitro and in vivo activities of DuP 105 and DuP 721. Antimicrob. Agents Chemother. 31:1791-1797.
92. Gregory WA, Brittelli DR, Wang C-L, Wuonola MA, McRipley RJ, Eustice DC, Eberly VS, Bartholomew PT, Slee AM, Forbes M. 1989. Antibacterials. Synthesis and structure-activity studies of 3-aryl-2-oxooxazolidines. 1. The B group. J. Med. Chem. 32:1673-1681.
93. Gregory WA, Brittelli DR, Wang C-LJ, Kezar HS III, Carlson RK, Park CH, Corless PF, Miller SJ, Rajagopalan P. 1990. Antibacterials. Synthesis and structure-activity studies of 3-aryl-2-oxooxazolidines. 2. The "A" group. J. Med. Chem. 33:2569-2578.
94. Park CH, Brittelli DR, Wang C-L, Marsh FD, Gregory WA, Wuonola MA, McRipley RJ, Eberly VS, Slee AM, Forbes M. 1992. Antibacterials. Synthesis and structure-activity studies of 3-aryl-2-oxazolidinones. 4. Multiply-substituted aryl derivatives. J. Med. Chem. 35:1156-1165.
95. Zhanel GG, Schroeder C, Vercaigne L, Gin AS, Embil J, Hoban DJ. 2001. A critical review of oxazolidinones: An alternative or replacement for glycopeptides and streptogramins? Can. J. Infect. Dis. 12:379-390.
96. Ford CW, Zurenko GE, Barbachyn MR. 2001. The discovery of linezolid, the first oxazolidinone antibacterial agent. Curr. Drug Targets Infect. Disord. 1:181-199.
97. Hutchinson DK. 2003. Oxazolidinone antibacterial agents: a critical review. Curr. Med. Chem. 3:1021-1042.
98. Toh SM, Xiong L, Arias CA, Villegas MV, Lolans K, Quinn J, Mankin AS. 2007. Acquisition of a natural resistance gene renders a clinical strain of methicillin-resistant Staphylococcus aureus resistant to the synthetic antibiotic linezolid. Mol. Microbiol. 64:1506-1514.
99. De Vriese AS, Van Coster Smet R J, Seneca S, Lovering A, Van Haute LL, Vanopdenbosch LJ, Martin JJ, Ceuterick-de Groote C, Vandecasteele S, Boelaert JR. 2006. Linezolid-induced inhibition of mitochondrial protein synthesis. Clin. Infect. Dis. 42:1111-1117.
100. Garrabou G, Soriano A, Lopez S, Guallar JP, Giralt M, Villarroya F, Marti{dotless}nez JA, Casademont J, Cardellach F, Mensa J, Miro. 2007. Reversible inhibition of mitochondrial protein synthesis during linezolid-related hyperlactatemia. Antimicrob. Agents Chemother. 51:962-967.
101. Das D, Lambert A, Tulkens PM, Muccioli GG, Van Bambeke F. 2012. Study of the cellular uptake and subcellular distribution of the oxazolidinone tedizolid (TZD) in murine J774 macrophages: lack of association with mitochondria. Abstr. 52nd Intersci. Conf. Antimicrob. Agents Chemother., abstr A-1291.
102. Lawrence L, Danese P, DeVito J, Franceschi F, Sutcliffe J. 2008. In vitro activities of the Rx-01 oxazolidinones against hospital and community pathogens. Antimicrob. Agents Chemother. 52:1653-1662.
103. Locke JB, Finn J, Hilgers M, Morales G, Rahawi S, Kedar GC, Picazo JJ, Im W, Shaw KJ, Stein JL. 2010. Structure-activity relationships of diverse oxazolidinones for linezolid-resistant Staphylococcus aureus strains possessing the cfr methyltransferase gene or ribosomal mutations. Antimicrob. Agents Chemother. 54:5337-5343.
104. Lemaire S, Tulkens PM, Van Bambeke F. 2010. Cellular pharmacokinetics of the novel biaryloxazolidinone radezolid in phagocytic cells: studies with macrophages and polymorphonuclear neutrophils. Antimicrob. Agents Chemother. 54:2540-2548.
105. Lemaire S, Kosowska-Shick K, Appelbaum PC, Verween G, Tulkens PM, Van Bambeke F. 2010. Cellular pharmacodynamics of the novel biaryloxazolidinone radezolid: studies with infected phagocytic and nonphagocytic cells, using Staphylococcus aureus, Staphylococcus epidermidis, Listeria monocytogenes, and Legionella pneumophila. Antimicrob. Agents Chemother. 54:2549-2559.
106. Zhu DM, Wang W, Huang YQ, Zhang YY. 2012. Antibacterial spectrum of oxazolidinone MRX-1: potent activity against multidrugresistant Gram-positive pathogens. Abstr. 52nd Intersci. Conf. Antimicrob. Agents Chemother., abstr F-1497.
107. Li CR, Li GQ, Hu XX, Zhang WX, Wang XK, Pang J, Lu X, Zhai QQ, Yuan H, Gordeev MF, Yang XY, You XF. 2012. Novel oxazolidinone MRX-1 is efficacious in mouse models of Gram-positive bacterial infections. Abstr. 52nd Intersci. Conf. Antimicrob. Agents Chemother., abstr F-1499.
108. Zhang J, Wu XJ, Huang J, Yu JC, Guo BN, Cao GY, Wu JF, Zhang KJ, Yuan H, Yuan ZY, Shi YG, Zhang YY. 2012. Single oral dose pharmacokinetics of MRX-1 in healthy subjects. Abstr. 52nd Intersci. Conf. Antimicrob. Agents Chemother., abstr F-1503.
109. Zhang J, Wu XJ, Huang J, Yu JC, Guo BN, Cao GY, Wu JF, Yuan H, Yuan ZY, Shi YG, Zhang YY. 2012. Hematological effect and pharmacokinetics of multiple oral dose MRX-1 in healthy subjects. Abstr. 52nd Intersci. Conf. Antimicrob. Agents Chemother., abstr F-1503.
110. Jeong JW, Jung SJ, Lee HH, Kim YZ, Park TK, Cho YL, Chae SE, Baek SY, Woo SH, Lee HS, Kwak JH. 2010. In vitro and in vivo activities of LCB01-0371, a new oxazolidinone. Antimicrob. Agents Chemother. 54: 5359-5362.
111. Johnson AP, Warner M, Livermore DM. 2002. In vitro activity of a novel oxazolidinone, AZD2563, against randomLy selected and multiresistant Gram-positive cocci. J. Antimicrob. Chemother. 50:89-93.
112. Howden Grayson BP, ML. 2006. Dumb and dumber-the potential waste of a useful antistaphylococcal agent: emerging fusidic acid resistance in Staphylococcus aureus. Clin. Infect. Dis. 42:394-400.
113. Kavanagh F, Hervey A, Robbins WJ. 1951. Antibiotic substances from basidiomycetes. 8. Pleurotus-multilus (fr.) Sacc. and pleurotuspasseckerianus pilat. Proc. Natl. Acad. Sci. U. S. A. 37:570-574.
114. Tang YZ, Liu YH, Chen J-X. 2012. Pleuromutilin and its derivatives-the lead compounds for novel antibiotics. Mini-Rev. Med. Chem. 12:53-61.
115. Hogenauer G. 1975. Mode of action of pleuromutilin derivatives-location and properties of pleuromutilin binding site on Escherichia coli ribosomes. Eur. J. Biochem. 52:93-98.
116. Katopodis GD, Grivea IN, Tsantsaridou AJ, Pournaras S, Petinaki E, Syrogiannopoulos GA. 2010. Fusidic acid and clindamycin resistance in community-associated, methicillin-resistant Staphylococcus aureus infections in children of Central Greece. BMC Infect. Dis. 10:351.
117. Castanheira M, Watters AA, Bell JM, Turnidge JD, Jones RN. 2010. Fusidic acid resistance rates and prevalence of resistance mechanisms among Staphylococcus spp. isolated in North America and Australia, 2007-2008. Antimicrob. Agents Chemother. 54:3614-3617.
118. Novak R. 2011. Are pleuromutilin antibiotics finally fit for human use? Ann. N. Y. Acad. Sci. 1241:71-81.
119. Hu C, Zou Y. 2009. Mutilins derivatives: from veterinary to humanused antibiotics. Mini-Rev. Med. Chem. 9:1397-1406.
120. Rittenhouse S, Biswas S, Broskey J, McCloskey L, Moore T, Vasey S, West J, Zalacain M, Zonis R, Payne D. 2006. Selection of retapamulin, a novel pleuromutilin for topical use. Antimicrob. Agents Chemother. 50:3882-3885.
121. Sader HS, Biedenbach DJ, Paukner S, Ivezic-Schoenfeld Z, Jones RN. 2012. Antimicrobial activity of the investigational pleuromutilin compound BC-3781 tested against Gram-positive organisms commonly associated with acute bacterial skin and skin structure infections. Antimicrob. Agents Chemother. 56:1619-1623.
122. Sader HS, Paukner S, Ivezic-Schoenfeld Z, Biedenbach DJ, Schmitz FJ, Jones RN. 2012. Antimicrobial activity of the novel pleuromutilin antibiotic BC-3781 against organisms responsible for community-acquired respiratory tract infections (CARTIs). J. Antimicrob. Chemother. 67: 1170-1175.
123. Prince WT, Obermayr F, Ivezic-Schoenfeld Z, Lell C, Wicha WW, Strickmann DB, Tack KJ, Novak R. 2011. A phase 2 study comparing the safety and efficacy of two doses of BC-3781 versus vancomycin in acute bacterial skin and skin structure infections (ABSSSI). Abstr. 51st Intersci. Conf. Antimicrob. Agents Chemother., abstr L-966.
124. Biedenbach DJ, Jones RN, Ivezic-Schoenfeld Z, Paukner S, Novak R. 2009. In vitro antibacterial spectrum of BC-7013, a novel pleuromutilin derivative for topical use in humans. Abstr. 49th Intersci. Conf. Antimicrob. Agents Chemother. abstr F1-1521.
125. Bush K. 2013. Proliferation and significance of clinically relevant β-lactamases. Ann. New York Acad. Sci. 1277:84-90.
126. Page MGP. 2013. Siderophore conjugates. Ann. N. Y. Acad. Sci. 1277: 115-126.
127. Page MGP, Dantier C, Desarbre E. 2010. In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli. Antimicrob. Agents Chemother. 54:2291-2302.
128. Mushtaq S, Warner M, Livermore D. 2010. Activity of the siderophore monobactam BAL30072 against multiresistant non-fermenters. J. Antimicrob. Chemother. 65:266-270.
129. Russo TA, Page MG, Beanan JM, Olson R, Hujer AM, Hujer KM, Jacobs M, Bajaksouzian S, Endimiani A, Bonomo RA. 2011. In vivo and in vitro activity of the siderophore monosulfactam BAL30072 against Acinetobacter baumannii. J. Antimicrob. Chemother. 66:867-873.
130. Nikaido H, Rosenberg EY. 1990. Cir and Fiu proteins in the outer membrane of Escherichia coli catalyze transport of monomeric catechols: study with beta-lactam antibiotics containing catechol and analogous groups. J. Bacteriol. 172:1361-1367.
131. Fung-Tomc J, Bush K, Minassian B, Kolek Flamm BR, Gradelski E, Bonner D. 1997. Antibacterial activity of BMS-180680, a new catecholcontaining monobactam. Antimicrob. Agents Chemother. 41:1010-1016.
132. Gould JK, Sattar A, Thommes P, Payne LJ, Stubbings W, Spickermann J, Daws G, Warn P. 2013. Efficacy of BAL30072 in murine thigh infection models of multi-resistant Gram-negative bacteria. Abstr. Eur. Congr. Clin. Microbiol. Infect. Dis, abstr P 908.
133. Fisher J, Charnas RL, Knowles JR. 1978. Kinetic studies on the inactivation of Escherichia coli RTEM beta-lactamase by clavulanic acid. Biochemistry 17:2180-2184.
134. Bush K, Macalintal C, Rasmussen BA, Lee VJ, Yang Y. 1993. Kinetic interactions of tazobactam with β-lactamases from all major structural classes. Antimicrob. Agents Chemother. 37:851-858.
135. Bush K, Jacoby GA, Medeiros AA. 1995. A functional classification scheme for β-lactamases and its correlation with molecular structure. Antimicrob. Agents Chemother. 39:1211-1233.
136. Takeda S, Nakai T, Wakai Y, Ikeda F, Hatano K. 2007. In vitro and in vivo activities of a new cephalosporin, FR264205, against Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 51:826-830.
137. Livermore DM, Mushtaq S, Ge Y. 2010. Chequerboard titration of cephalosporin CXA-101 (FR264205) and tazobactam versus betalactamase-producing Enterobacteriaceae. J. Antimicrob. Chemother. 65: 1972-1974.
138. Titelman E, Karlsson IM, Ge Y, Giske CG. 2011. In vitro activity of CXA-101 plus tazobactam (CXA-201) against CTX-M-14-and CTX-M-15-producing Escherichia coli and Klebsiella pneumoniae. Diagn. Microbiol. Infect. Dis. 70:137-141.
139. Livermore DM, Mushtaq S, Ge Y, Warner M. 2009. Activity of cephalosporin CXA-101 (FR264205) against Pseudomonas aeruginosa and Burkholderia cepacia group strains and isolates. Int. J. Antimicrob. Agents 34:402-406.
140. Stachyra T, Pechereau MC, Bruneau JM, Claudon M, Frere JM, Miossec C, Coleman K, Black MT. 2010. Mechanistic studies of the inactivation of TEM-1 and P99 by NXL104, a novel non-beta-lactam beta-lactamase inhibitor. Antimicrob. Agents Chemother. 54:5132-5138.
141. Ehmann DE, Jahic H, Ross PL, Gu RF, Hu J, Kern G, Walkup GK, Fisher SL. 2012. Avibactam is a covalent, reversible, non-beta-lactam beta-lactamase inhibitor. Proc. Natl. Acad. Sci. U. S. A. 109:11663-11668.
142. Lagace-Wiens PR, Tailor F, Simner P, DeCorby M, Karlowsky JA, Walkty A, Hoban DJ, Zhanel GG. 2011. Activity of NXL104 in combination with beta-lactams against genetically characterized Escherichia coli and Klebsiella pneumoniae isolates producing class A extended-spectrum beta-lactamases and class C beta-lactamases. Antimicrob. Agents Chemother. 55:2434-2437.
143. Livermore DM, Mushtaq S, Warner M, Miossec C, Woodford N. 2008. NXL104 combinations versus Enterobacteriaceae with CTX-M extended-spectrum beta-lactamases and carbapenemases. J. Antimicrob. Chemother. 62:1053-1056.
144. Endimiani Choudhary A, Y, Bonomo RA. 2009. In vitro activity of NXL104 in combination with beta-lactams against Klebsiella pneumoniae isolates producing KPC carbapenemases. Antimicrob. Agents Chemother. 53:3599-3601.
145. Stachyra T, Levasseur P, Pechereau MC, Girard AM, Claudon M, Miossec C, Black MT. 2009. In vitro activity of the β-lactamase inhibitor NXL104 against KPC-2 carbapenemase and Enterobacteriaceae expressing KPC carbapenemases. J. Antimicrob. Chemother. 64:326-329.
146. Livermore DM, Mushtaq Warner M, Zhang J, Maharjan Doumith SM, Woodford N. 2011. Activities of NXL104 combinations with ceftazidime and aztreonam against carbapenemase-producing Enterobacteriaceae. Antimicrob. Agents Chemother. 55:390-394.
147. Aktas Z, Kayacan C, Oncul O. 2012. In vitro activity of avibactam (NXL104) in combination with β-lactams against Gram-negative bacteria, including OXA-48 β-lactamase-producing Klebsiella pneumoniae. Int. J. Antimicrob. Agents 39:86-89.
148. Walkty A, DeCorby M, Lagace-Wiens PR, Karlowsky JA, Hoban DJ, Zhanel GG. 2011. In vitro activity of ceftazidime combined with NXL104 versus Pseudomonas aeruginosa isolates obtained from patients in Canadian hospitals (CANWARD 2009 study). Antimicrob. Agents Chemother. 55:2992-2994.
149. Mushtaq S, Warner M, Livermore DM. 2010. In vitro activity of ceftazidime+NXL104 against Pseudomonas aeruginosa and other nonfermenters. J. Antimicrob. Chemother. 65:2376-2381.
150. Levasseur P, Girard AM, Claudon M, Goossens H, Black MT, Coleman K, Miossec C. 2012. In vitro antibacterial activity of the ceftazidimeavibactam (NXL104) combination against Pseudomonas aeruginosa clinical isolates. Antimicrob. Agents Chemother. 56:1606-1608.
151. Kosowska-Shick K, McGhee PL, Appelbaum PC. 2010. Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae. Antimicrob. Agents Chemother. 54:1670-1677.
152. Keel RA, Crandon JL, Nicolau DP. 2011. Efficacy of human simulated exposures of ceftaroline administered at 600 milligrams every 12 hours against phenotypically diverse Staphylococcus aureus isolates. Antimicrob. Agents Chemother. 55:4028-4032.
153. Mushtaq S, Warner M, Williams G, Critchley I, Livermore DM. 2010. Activity of chequerboard combinations of ceftaroline and NXL104 versus beta-lactamase-producing Enterobacteriaceae. J. Antimicrob. Chemother. 65:1428-1432.
154. Karlowsky JA, Adam HJ, Decorby MR, Lagace-Wiens PR, Hoban DJ, Zhanel GG. 2011. In vitro activity of ceftaroline against gram-positive and gram-negative pathogens isolated from patients in Canadian hospitals in 2009. Antimicrob. Agents Chemother. 55:2837-2846.
155. Castanheira M, Sader HS, Farrell DJ, Mendes RE, Jones RN. 2012. Activity of ceftaroline-avibactam tested against Gram-negative organism populations, including strains expressing one or more β-lactamases and methicillin-resistant Staphylococcus aureus carrying various staphylococcal cassette chromosome mec types. Antimicrob. Agents Chemother. 56:4779-4785.
156. Livermore DM, Mushtaq S, Barker K, Hope R, Warner M, Woodford N. 2012. Characterization of beta-lactamase and porin mutants of Enterobacteriaceae selected with ceftaroline + avibactam (NXL104). J. Antimicrob. Chemother. 67:1354-1358.
157. Jacoby GA. 2009. AmpC beta-lactamases. Clin. Microbiol. Rev. 22:161-182.
158. Young K, Raghoobar SL, Hairston NN, Painter RE, Racine F, Dorson KL, Hermes JD, Hammond ML, Motyl MR. 2010. In vitro activity of the class A and C β-lactamase inhibitor MK-7655. Abstr. 50th Intersci. Conf. Antimicrob. Agents Chemother., abstr F1-2139.
159. Mangion IK, Ruck RT, Rivera N, Huffman MA, Shevlin M. 2011. A concise synthesis of a β-lactamase inhibitor. Org. Lett. 13:5480-5483.
160. Hirsch EB, Ledesma KR, Chang KT, Schwartz MS, Motyl MR, Tam VH. 2012. In vitro activity of MK-7655, a novel β-lactamase inhibitor, in combination with imipenem against carbapenem-resistant Gramnegative bacteria. Antimicrob. Agents Chemother. 56:3753-3757.
161. Bhagunde P, Chang KT, Hirsch EB, Ledesma KR, Nikolaou M, Tam VH. 2012. A novel modeling framework to guide design of optimal dosing strategies for beta-lactamase inhibitors. Antimicrob. Agents Chemother. 56:2237-2240.
162. Chen HY, Livermore DM. 1994. In-vitro activity of biapenem, compared with imipenem and meropenem, against Pseudomonas aeruginosa strains and mutants with known resistance mechanisms. J. Antimicrob. Chemother. 33:949-958.
163. Sader HS, Jones RN. 1993. Antimicrobial activity of the new carbapenem biapenem compared to imipenem, meropenem and other broad-spectrum beta-lactam drugs. Eur. J. Clin. Microbiol. Infect. Dis. 12:384-391.
164. Yang Y, Bhachech N, Bush K. 1995. Biochemical comparison of imipenem, meropenem and biapenem: permeability, binding to penicillinbinding proteins, and stability to hydrolysis by β-lactamases. J. Antimicrob. Chemother. 35:75-84.
165. Gomi K, Fujimura S, Fuse K, Takane H, Nakano Y, Kariya Y, Kikuchi T, Kurokawa I, Tokue Y, Watanabe A. 2011. Antibacterial activity of carbapenems against clinical isolates of respiratory bacterial pathogens in the northeastern region of Japan in 2007. J. Infect. Chemother. 17:200-206.
166. Day IP, Goudie J, Nishiki K, Williams PD. 1995. Correlation between in vitro and in vivo models of proconvulsive activity with the carbapenem antibiotics, biapenem, imipenem/cilastatin and meropenem. Toxicol. Lett. 76:239-243.
167. Hecker SJ, Reddy KR, Totrov M, Hirst GC, Lomovskaya O, Griffith DC, King P, Tsivkovski R, Sun D, Sabet M, Taraz Z, Dudley MN. 2012. Discovery of RPX7009, a broad-spectrum beta-lactamase inhibitor with utility vs. class A serine carbapenemases. Abstr. 52nd Intersci. Conf. Antimicrob. Agents Chemother. http://www.icaac.org/.
168. Lomovskaya O, Tsivkovsky R, Griffith D, Hecker SJ, Dudley MN. 2012. Biochemical characterization of the beta-lactamase inhibitor RPX7009. Abstr. 52nd Intersci. Conf. Antimicrob. Agents Chemother., abstr F-849.
169. Sabet M, Tarazi Z, Lomovskaya O, Hecker SJ, Dudley MN, Griffith DC. 2012. In vivo efficacy of the beta-lactamase inhibitor RPX7009 combined with the carbapenem RPX2003 against KPC-producing K. pneumoniae. Abstr. 52nd Intersci. Conf. Antimicrob. Agents Chemother., abstr F-858.
170. Zervosen A, Bouillez A, Herman A, Amoroso A, Joris B, Sauvage E, Charlier P, Luxen A. 2012. Synthesis and evaluation of boronic acids as inhibitors of penicillin binding proteins of classes A, B and C. Bioorg. Med. Chem. 20:3915-3924.
171. Powers RA, Blazquez J, Weston GS, Morosini MI, Baquero F, Shoichet BK. 1999. The complexed structure and antimicrobial activity of a non-betalactam inhibitor of AmpC beta-lactamase. Protein Sci. 8:2330-2337.
172. Tan Q, Ogawa AM, Painter RE, Park YW, Young K, DiNinno FP. 2010. 4,7-Dichloro benzothien-2-yl sulfonylaminomethyl boronic acid: first boronic acid-derived beta-lactamase inhibitor with class A, C, andD activity. Bioorg. Med. Chem. Lett. 20:2622-2624.
173. Ke Sampson W, JM, Ori C, Prati F, Drawz SM, Bethel CR, Bonomo RA, van den Akker F. 2011. Novel insights into the mode of inhibition of class A SHV-1 beta-lactamases revealed by boronic acid transition state inhibitors. Antimicrob. Agents Chemother. 55:174-183.
174. Griffith DC, Sabet M, Tarazi Z, Tsivkovski R, Lomovskaya O, Hecker SJSJ, Dudley MN. 2012. Nonclinical toxicology and safety profile of the beta-lactamase inhibitor RPX7009. Abstr. 52nd Intersci. Conf. Antimicrob. Agents Chemother. http://www.icaac.org/.
175. Zasloff M. 1987. Magainins, A class of antimicrobial peptides from Xenopus skin: isolation, characterization of two active forms, and partial cDNA sequence of a precursor. Proc. Natl. Acad. Sci. U. S. A. 84:5449-5453, 1987.
176. Yount NY, Yeaman MR. 2012. Emerging themes and therapeutic prospects for anti-infective peptides. Annu. Rev. Pharmacol. Toxicol. 52: 337-360.
177. Seo MD, Won HS, Kim JH, Mishig-Ochir T, Lee BJ. 2012. Antimicrobial peptides for therapeutic applications: a review. Molecules 17:12276-12286.
178. Mensa B, Kim YH, Choi S, Scott R, Caputo GA, DeGrado WF. 2011. Antibacterial mechanism of action of arylamide foldamers. Antimicrob. Agents Chemother. 55:5043-5053.
179. Morrisey I, Dallow J, Siegwart E, Smith A, Scott R, Korczak B. 2012. The activity of PMX-30063 against staphylococci and streptococci. Abstr. 22nd Eur. Congr. Clin. Microbiol. Infect. Dis., abstr P-1458.
180. Srinivas N, Jetter P, Ueberbacher BJ, Werneburg M, Zerbe K, Steinmann J, Van der Meijden B, Bernardini F, Lederer A, Dias RL, Misson PE, Henze H, Zumbrunn J, Gombert FO, Obrecht D, Hunziker P, Schauer S, Ziegler U, Käch A, Eberl L, Riedel K, DeMarco SJ, Robinson JA. 2010. Peptidomimetic antibiotics target outer-membrane biogenesis in Pseudomonas aeruginosa. Science 327:1010-1013.
181. Werneburg M, Zerbe K, Juhas M, Bigler L, Stalder U, Kaech A, Ziegler U, Obrecht D, Eberl L, Robinson JA. 2012. Inhibition of lipopolysaccharide transport to the outer membrane in Pseudomonas aeruginosa by peptidomimetic antibiotics. Chembiochem 13:1767-1775.
182. Wilbraham S, DeMarco S, Ograbek A, Agren J, Wach A, Obrecht D, Demkowski K. 2011. Phase 1 study with the novel Pseudomonas aeruginosa antibiotic POL7080 in healthy volunteers. Abstr. 21st Eur. Congr. Clin. Microbiol. Infect. Dis.-27th Int. Congr. Chemother. abstr P 1513.
183. Kollef MH, Golan Y, Micek ST, Shorr AF, Restrepo MI. 2011. Appraising contemporary strategies to combat multidrug resistant Gramnegative bacterial infections-proceedings and data from the Gramnegative resistance summit. Clin. Infect. Dis. 53(Suppl 2):S33-S55.
184. Sader HS, Farrell DJ, Jones RN. 2011. Antimicrobial activity of daptomycin tested against gram-positive strains collected in European hospitals: results from 7 years of resistance surveillance (2003-2009). J. Chemother. 23:200-206.
185. Kamboj M, Cohen N, Gilhuley K, Babady NE, Seo SK, Sepkowitz KA. 2011. Emergence of daptomycin-resistant VRE: experience of a single institution. Infect. Control Hosp. Epidemiol. 32:391-394.
186. Kelley PG, Gao W, Ward PB, Howden BP. 2011. Daptomycin nonsusceptibility in vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous-VISA (hVISA): implications for therapy after vancomycin treatment failure. J. Antimicrob. Chemother. 66:1057-1060.
187. Richter SS, Satola SW, Crispell EK, Heilmann KP, Dohrn CL, Riahi F, Costello AJ, Diekema DJ, Doern GV. 2011. Detection of Staphylococcus aureus isolates with heterogeneous intermediate-level resistance to vancomycin in the United States. J. Clin. Microbiol. 49:4203-4207.
188. Flamm RK, Farrell DJ, Mendes RE, Ross JF, Sader HS, Jones RN. 2012. LEADER surveillance program results for 2010: an activity and spectrum analysis of linezolid using 6801 clinical isolates from the United States (61 medical centers). Diagn. Microbiol. Infect. Dis. 74:54-61.
189. Steiert M, Schmitz FJ. 2002. Dalbavancin (Biosearch Italia/Versicor). Curr. Opin. Invest. Drugs 3:229-233.
190. Barrett JF. 2001. Oritavancin. Eli Lilly & Co. Curr. Opin. Invest. Drugs 2:1039-1044.
191. Abbanat D, Macielag M, Bush K. 2003. Novel antibacterial agents for the treatment of serious Gram-positive infections. Expert Opin. Invest. Drugs 379-399.
192. Bozdogan B, Esel D, Whitener C, Browne FA, Appelbaum PC. 2003. Antibacterial susceptibility of a vancomycin-resistant Staphylococcus au-reus strain isolated at the Hershey Medical Center. J. Antimicrob. Chemother. 52:864-868.
193. Candiani G, Abbondi M, Borgonovi M, Romano G, Parenti F. 1999. In-vitro and in-vivo antibacterial activity of BI 397, a new semi-synthetic glycopeptide antibiotic. J. Antimicrob. Chemother. 44:179-192.
194. Allen NE, Nicas TI. 2003. Mechanism of action of oritavancin and related glycopeptide antibiotics. FEMS Microbiol. Rev. 26:511-532.
195. Zhanel GG, Calic D, Schweizer F, Zelenitsky S, Adam H, Lagace-Wiens PR, Rubinstein E, Gin AS, Hoban DJ, Karlowsky JA. 2010. New lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancin. Drugs 70:859-886.
196. Dunbar L, Milata MJ, McClure T, Wasilewski MM, Team SS. 2011. Comparison of the efficacy and safety of oritavancin front-loaded dosing regimens to daily dosing: an analysis of the SIMPLIFI trial. Antimicrob. Agents Chemother. 55:3476-3484.
197. Chen DZ, Patel DV, Hackbarth CJ, Wang W, Dreyer G, Young DC, Margolis PS, Wu C, Ni ZJ, Trias J, White RJ, Yuan Z. 2000. Actinonin, a naturally occurring antibacterial agent, is a potent deformylase inhibitor. Biochemistry 39:1256-1262.
198. Guilloteau JP, Mathieu M, Giglione C, Blanc V, Dupuy A, Chevrier M, Gil P, Famechon A, Meinnel T, Mikol V. 2002. The crystal structures of four peptide deformylases bound to the antibiotic actinonin reveal two distinct types: a platform for the structure-based design of antibacterial agents. J. Mol. Biol. 320:951-962.
199. Kreusch A, Spraggon G, Lee CC, Klock H, McMullan D, Ng K, Shin T, Vincent J, Warner I, Ericson C, Lesley SA. 2003. Structure analysis of peptide deformylases from Streptococcus pneumoniae, Staphylococcus aureus, Thermotoga maritima and Pseudomonas aeruginosa: snapshots of the oxygen sensitivity of peptide deformylase. J. Mol. Biol. 330:309-321.
200. Serero A, Giglione C, Sardini A, Martinez-Sanz J, Meinnel T. 2003. An unusual peptide deformylase features in the human mitochondrial Nterminal methionine excision pathway. J. Biol. Chem. 278:52953-52963.
201. Jain R, Chen D, White RJ, Patel DV, Yuan Z. 2005. Bacterial peptide deformylase inhibitors: a new class of antibacterial agents. Curr. Med. Chem. 12:1607-1621.
202. Payne DJ, Gwynn MN, Holmes DJ, Pompliano DJ. 2007. Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat. Rev. Drug Discov. 6:29-40.
203. Chen D, Hackbarth C, Ni ZJ, Wu C, Wang W, Jain R, He Y, Bracken K, Weidmann B, Patel DV, Trias J, White RJ, Yuan Z. 2004. Peptide deformylase inhibitors as antibacterial agents: identification of VRC3375, a proline-3-alkylsuccinyl hydroxamate derivative, by using an integrated combinatorial and medicinal chemistry approach. Antimicrob. Agents Chemother. 48:250-261.
204. Bouchillon S, Hackel M, Hoban D, Zalacain M, Butler D. 2010. In vitro activity of GSK1322322, a novel peptide deformylase inhibitor, against 4,836 pathogens from skin and soft tissue infections and respiratory tract infections. Abstr. 50th Intersci. Conf. Antimicrob. Agents Chemother., abstr F1-2112.
205. Ross JE, Scangarella-Oman NE, Miller LA, Sader HS, Jones RN. 2011. Determination of disk diffusion and MIC quality control ranges for GSK1322322, a novel peptide deformylase inhibitor. J. Clin. Microbiol. 49:3928-3930.
206. Naderer OJ, Rodvold KA, Jones LS, Zhu JZ, Dumont EF. 2012. Penetration of GSK1322322 (GSK322) into epithelial lining fluid (ELF) and alveolar macrophages (AM) as determined by bronchoalveolar lavage (BAL). Abstr. 52nd Intersci. Conf. Antimicrob. Agents Chemother. http://www.icaac.org/.
207. Fan F, Yan K, Wallis NG, Reed S, Moore TD, Rittenhouse SF, DeWolf WE, Jr, Huang J, McDevitt D, Miller WH, Seefeld MA, Newlander KA, Jakas DR, Head MS, Payne DJ. 2002. Defining and combating the mechanisms of triclosan resistance in clinical isolates of Staphylococcus aureus. Antimicrob. Agents Chemother. 46:3343-3347.
208. Moir DT. 2005. Identification of inhibitors of bacterial enoyl-acyl carrier protein reductase. Curr. Drug Targets Infect. Disord. 5:297-305.
209. Kitagawa H, Ozawa T, Takahata S, Iida M, Saito J, Yamada M. 2007. Phenylimidazole derivatives of 4-pyridone as dual inhibitors of bacterial enoyl-acyl carrier protein reductases FabI and FabK. J. Med. Chem. 50: 4710-4720.
210. Escaich S, Prouvensier L, Saccomani M, Durant L, Oxoby M, Gerusz V, Moreau F, Vongsouthi V, Maher K, Morrissey I, Soulama-Mouze C. 2011. The MUT056399 inhibitor of FabI is a new antistaphylococcal compound. Antimicrob. Agents Chemother. 55:4692-4697.
211. Gerusz V, Denis A, Faivre F, Bonvin Y, Oxoby M, Briet S, LeFralliec G, Oliveira C, Desroy N, Raymond C, Peltier L, Moreau F, Escaich S, Vongsouthi V, Floquet S, Drocourt E, Walton A, Prouvensier L, Saccomani M, Durant L, Genevard JM, Sam-Sambo V, Soulama-Mouze C. 2012. From triclosan toward the clinic: discovery of nonbiocidal, potent FabI inhibitors for the treatment of resistant bacteria. J. Med. Chem. 55:9914-9928.
212. Kitagawa H, Kumura K, Takahata S, Iida M, Atsumi K. 2007. 4-Pyridone derivatives as new inhibitors of bacterial enoyl-ACP reductase FabI. Bioorg. Med. Chem. 15:1106-1116.
213. Goh S, Good L. 2008. Plasmid selection in Escherichia coli using an endogenous essential gene marker. BMC Biotechnol. 8:61.
214. Ramnauth J, Surman MD, Sampson PB, Forrest B, Wilson J, Freeman E, Manning DD, Martin F, Toro A, Domagala M, Awrey DE, Bardouniotis Kaplan EN, Berman J, Pauls HW. 2009. 2,3,4,5-Tetrahydro-1H-pyrido[2,3-b and e][1,4]diazepines as inhibitors of the bacterial enoyl ACP reductase, FabI. Bioorg. Med. Chem. Lett. 19:5359-5362.
215. Sampson PB, Picard C, Handerson S, McGrath TE, Domagala M, Leeson A, Romanov V, Awrey DE, Thambipillai D, Bardouniotis E, Kaplan N, Berman JM, Pauls HW. 2009. Spiro-naphthyridinone piperidines as inhibitors of S. aureus and E. coli enoyl-ACP reductase (FabI). Bioorg. Med. Chem. Lett. 19:5355-5358.
216. Karlowsky JA, Kaplan N, Hafkin B, Hoban DJ, Zhanel GG. 2009. AFN-1252, a FabI inhibitor, demonstrates a Staphylococcus-specific spectrum of activity. Antimicrob. Agents Chemother. 53:3544-3548.
217. Kaplan N, Albert M, Awrey D, Bardouniotis E, Berman J, Clarke T, Dorsey M, Hafkin B, Ramnauth J, Romanov V, Schmid MB, Thalakada R, Yethon J, Pauls HW. 2012. Mode of action, in vitro activity, and in vivo efficacy of AFN-1252, a selective antistaphylococcal FabI inhibitor. Antimicrob. Agents Chemother. 56:5865-5874.
218. Soulama C, Bryskier A, Chassard D, Fischer S. 2010. MUT056399: a single intravenous ascending dose study in healthy human volunteers. Abstr. 50th Intersci. Conf. Antimicrob. Agents Chemother., abstr 1969.
219. Grosset JH, Singer TG, Bishai WR. 2012. New drugs for the treatment of tuberculosis: hope and reality. Int. J. Tuberc. Lung Dis. 16:1005-1014.
220. Villemagne B, Crauste C, Flipo M, Baulard AR, Déprez B, Willand N. 2012. Tuberculosis: the drug development pipeline at a glance. Eur. J. Med. Chem. 51:1-16.
221. Blondeau JM. 1999. Expanded activity and utility of the new fluoroquinolones: a review. Clin. Ther. 21:3-40.
222. Rodríguez JC, Ruiz M, Climent A, Royo G. 2001. In vitro activity of four fluoroquinolones against Mycobacterium tuberculosis. Int. J. Antimicrob. Agents 17:229-231.
223. Takiff H, Guerrero E. 2011. Current prospects for the fluoroquinolones as first-line tuberculosis therapy. Antimicrob. Agents Chemother. 55: 5421-5429.
224. Aubry A, Pan XS, Fisher LM, Jarlier V, Cambau EE. 2004. Mycobacterium tuberculosis DNA gyrase: interaction with quinolones and correlation with antimycobacterial drug activity. Antimicrob. Agents Chemother. 48:1281-1288.
225. Alvirez-Freites EJ, Carter JL, Cynamon MH. 2002. In vitro and in vivo activities of gatifloxacin against Mycobacterium tuberculosis, Antimicrob. Agents Chemother. 46:1022-1025.
226. Lubasch A, Keller I, Borner K, Koeppe P, Lode H. 2000. Comparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, trovafloxacin, and moxifloxacin after single oral administration in healthy volunteers. Antimicrob. Agents Chemother. 44:2600-2603.
227. Pletz MWR, De Roux A, Roth A, Neumann KH, Mauch H, Lode H. 2004. Early bactericidal activity of moxifloxacin in treatment of pulmonary tuberculosis: a prospective, randomized study. Antimicrob. Agents Chemother. 48:780-782.
228. Rustomjee R, Lienhardt C, Kanyok T, Davies GR, Levin J, Mthiyane T, Reddy C, Sturm AW, Sirgel FA, Allen J, Coleman DJ, Fourie B, Mitchison DA. 2008. A phase 1I study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int. J. Tuberc. Lung Dis. 12:128-138.
229. Gler MT, Skripconoka V, Sanchez-Garavito E, Xiao H, Cabrera-Rivero JL, Vargas-Vasquez DE, Gao M, Awad M, Park SK, Shim TS, Suh GY, Danilovits M, Ogata H, Kurve A, Chang J, Suzuki K, Tupasi T, Koh WJ, Seaworth B, Geiter LJ, Wells CD. 2012. Delamanid for multidrugresistant pulmonary tuberculosis. N. Engl. J. Med. 366:2151-2160.
230. Matsumoto M, Hashizume H, Tomishige T, Kawasaki M, Tsubouchi H, Sasaki H, Shimokawa Y, Komatsu M. 2006. OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice. PLoS Med. 3:e466. doi:10.1371/journal.pmed.0030466.
231. Stover CK, Warrener P, VanDevanter DR, Sherman DR, Arain TM, Langhorne MH, Anderson SW, Towell JA, Yuan Y, McMurray DN, Kreiswirth BN, Barry CE, Baker WR. 2000. A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature 405: 962-966.
232. Lenaerts AJ, Gruppo V, Marietta KS, Johnson CM, Driscoll DK, Tompkins NM, Rose JD, Reynolds RC, Orme IM. 2005. Preclinical testing of the nitroimidazopyran PA-824 for activity against Mycobacterium tuberculosis in a series of in vitro and in vivo models. Antimicrob. Agents Chemother. 49:2294-2301.
233. Diacon AH, Dawson R, von Groote-Bidlingmaier F, Symons G, Venter A, Donald PR, van Niekerk C, Everitt D, Winter H, Becker P, Mendel CM, Spigelman MK. 2012. 14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial. Lancet 380:986-993.
234. Sacksteder KA, Protopopova M, Barry CE, 3rd, Andries K, Nacy CA. 2012. Discovery and development of SQ109: a new antitubercular drug with a novel mechanism of action. Future Microbiol. 7:823-837.
235. Tahlan K, Wilson R, Kastrinsky DB, Arora K, Nair V, Fischer E, Barnes SW, Walker JR, Alland D, Barry CE, 3rd, Boshoff HI. 2012. SQ109 targets MmpL3, a membrane transporter of trehalose monomycolate involved in mycolic acid donation to the cell wall core of Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 56:1797-1809.
236. Protopopova M, Hanrahan C, Nikonenko B, Samala R, Chen P, Gearhart J, Einck L, Nacy CA. 2005. Identification of a new antitubercular drug candidate, SQ109, from a combinatorial library of 1,2-ethylenediamines. J. Antimicrob. Chemother. 56:968-974.
237. Lee M, Lee J, Carroll MW, Choi H, Min S, Song T, Via LE, Goldfeder LC, Kang E, Jin B, Park H, Kwak H, Kim H, Jeon HS, Jeong I, Joh JS, Chen RY, Olivier KN, Shaw PA, Follmann D, Song SD, Lee JK, Lee D, Kim CT, Dartois V, Park SK, Cho SN, Barry CE, 3rd. 2012. Linezolid for treatment of chronic extensively drug-resistant tuberculosis. N. Engl. J. Med. 367:1508-1518.
238. Migliori GB, Eker B, Richardson MD, Sotgiu G, Zellweger JP, Skrahina A, Ortmann J, Girardi E, Hoffmann H, Besozzi G, Bevilacqua N, Kirsten D, Centis R, Lange C, TBNET Study Group. 2009. A retrospective TBNET assessment of linezolid safety, tolerability and efficacy in multidrug-resistant tuberculosis. Eur. Respir. J. 34:387-393.
239. Alffenaar JW, van der Laan T, Simons S, van der Werf TS, van de Kasteele PJ, de Neeling H, van Soolingen D. 2011. Susceptibility of clinical isolates to a potentially less toxic derivate of linezolid, PNU-100480. Antimicrob. Agents Chemother. 55:1287-1289.
240. Cynamon MH, Klemens SP, Sharpe CA, Chase S. 1999. Activities of several novel oxazolidinones against Mycobacterium tuberculosis in a murine model. Antimicrob. Agents Chemother. 43:1189-1191.
241. Williams KN, Stover CK, Zhu T, Tasneen R, Tyagi S, Grosset JH, Nuermberger E. 2009. Promising antituberculosis activity of the oxazolidinone PNU-100480 relative to that of linezolid in a murine model. Antimicrob. Agents Chemother. 53:1314-1319.
242. Balasubramanian V, Gaonkar S, Solapure S, Sambandamurthy V, Shandil RK, Mahesh KN, Sharma S, Kaur P, Deepthi R, Subbulakshmi V, Ramya V, Ramachandran V, Reddy J, Giridhar J, Deshpande A, Bharath S, Kumar N, Balganesh M, Nandi V, Wright L, Melnick D. 2011. AZD5847, an oxazolidinone for the treatment of tuberculosis: preclinical studies. Abstr. 51st Intersci. Conf. Antimicrob. Agents Chemother., abstr F1-1364.
243. Reele S, Xiao AJ, Das S, Balasubramanian V, Melnick D. 2011. A 14 day multiple ascending dose study with AZD5847 is well tolerated at predicted exposure for treatment of tuberculosis (TB). Abstr. 51st Intersci. Conf. Antimicrob. Agents Chemother., abstr A1-1735.
244. Bogatcheva E, Hanrahan C, Nikonenko B, de los Santos G, Reddy V, Chen P, Barbosa F, Einck L, Nacy C, Protopopova M. 2011. Identification of SQ609 as a lead compound from a library of dipiperidines. Bioorg. Med. Chem. Lett. 21:5353-5357.
245. Gerding DN. 2012. Clostridium difficile infection prevention: biotherapeutics, immunologics, and vaccines. Discov. Med. 13:75-83.
246. Lessa FC, Gould CV, McDonald LC. 2012. Current status of Clostridium difficile infection epidemiology. Clin. Infect. Dis. 55(Suppl. 2):S65-S70.
247. McDonald LC, Killgore GE, Thompson A, Owens RC, Jr, Kazakova SV, Sambol SP, Johnson S, Gerding DN. 2005. An epidemic, toxin gene-variant strain of Clostridium difficile. N. Engl. J. Med. 353:2433-2441.
248. Mascio CT, Mortin LI, Howland KT, Van Praagh AD, Zhang S, Arya A, Chuong CL, Kang C, Li T, Silverman JA. 2012. In vitro and in vivo characterization of CB-183,315, a novel lipopeptide antibiotic for treatment of Clostridium difficile. Antimicrob. Agents Chemother. 56:5023-5030.
249. Snydman DR, Jacobus NV, McDermott LA. 2012. Activity of a novel cyclic lipopeptide, CB-183,315, against resistant Clostridium difficile and other Gram-positive aerobic and anaerobic intestinal pathogens. Antimicrob. Agents Chemother. 56:3448-3452.
250. LaMarche MJ, Leeds JA, Amaral A, Brewer JT, Bushell SM, Deng G, Dewhurst JM, Ding J, Dzink-Fox J, Gamber G, Jain A, Lee K, Lee L, Lister T, McKenney D, Mullin S, Osborne C, Palestrant D, Patane MA, Rann EM, Sachdeva M, Shao J, Tiamfook S, Trzasko A, Whitehead L, Yifru A, Yu D, Yan W, Zhu Q. 2012. Discovery of LFF571: an investigational agent for Clostridium difficile infection. J. Med. Chem. 55:2376-2387.
251. Citron DM, Tyrrell KL, Merriam CV, Goldstein EJ. 2012. Comparative in vitro activities of LFF571 against Clostridium difficile and 630 other intestinal strains of aerobic and anaerobic bacteria. Antimicrob. Agents Chemother. 56:2493-2503.
252. Ting LS, Praestgaard J, Grunenberg N, Yang JC, Leeds JA, Pertel P. 2012. A first-in-human, randomized, double-blind, placebo-controlled, single-and multiple-ascending oral dose study to assess the safety and tolerability of LFF571 in healthy volunteers. Antimicrob. Agents Chemother. 56:5946-5951.
253. Crowther GS, Baines SD, Todhunter SL, Freeman J, Chilton CH, Wilcox MH. 2013. Evaluation of NVB302 versus vancomycin activity in an in vitro human gut model of Clostridium difficile infection. J. Antimicrob. Chemother. 68:168-176.
254. Livermore DM. 2012. Fourteen years in resistance. Int. J. Antimicrob. Agents 39:283-294.
255. Fernandez J, Hilliard JJ, Morrow BJ, Melton JL, Flamm RK, Barron AM, Lynch AS. 2011. Efficacy of a new fluoroquinolone, JNJ-Q2, in murine models of Staphylococcus aureus and Streptococcus pneumoniae skin, respiratory, and systemic infections. Antimicrob. Agents Chemother. 55:5522-5528.
256. Starosta AL, Fyfe C, Wilson DN, Sutcliffe J, Grossman T. 2010. Targetand resistance-based mechanistic studies with fluorocyclines TP-434 and TP-271. Abstr. 50th Intersci. Conf. Antimicrob. Agents Chemother., abstr F-2160.
257. Kanafani ZA, Corey GR. 2012. Tedizolid (TR-701): a new oxazolidinone with enhanced potency. Expert Opin. Invest. Drugs 21:515-522.
258. Koripella RK, Chen Y, Peisker K, Koh CS, Selmer M, Sanyal S. 2012. Mechanism of elongation factor-G-mediated fusidic acid resistance and fitness compensation in Staphylococcus aureus. J. Biol. Chem. 287:30257-30267.
259. Craft JC, Moriarty SR, Clark K, Scott D, Degenhardt TP, Still JG, Corey GR, Das A, Fernandes P. 2011. A randomized, double-blind phase 2 study comparing the efficacy and safety of an oral fusidic acid loading-dose regimen to oral linezolid for the treatment of acute bacterial skin and skin structure infections. Clin. Infect. Dis. 52(Suppl 7): S520-S526.
260. Kronvall G. 2010. Antimicrobial resistance 1979-2009 at Karolinska hospital, Sweden: normalized resistance interpretation during a 30-year follow-up on Staphylococcus aureus and Escherichia coli resistance development. APMIS 118:621-639.